Veradermics (MANE)
Develops extended-release oral minoxidil for male and female pattern hair loss.
$99.20
Pre-market+0.75 (+0.76%)
At close$98.45(+0.96%)
In millions of USD, except per-share figures
| In millions | Q4 FY24Dec 2024 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|
| 6 | 23 | 30 | 30 | |
| Research & development | 5 | 18 | 21 | 19 |
| 1 | 5 | 9 | 11 | |
| General & administrative | 1 | 5 | 9 | 11 |
| Operating income | −6 | −23 | −30 | −30 |
| 0 | 1 | 3 | 6 | |
| Interest income | 0 | 1 | 2 | 5 |
| Interest expense | 0 | 1 | 0 | 0 |
| Other non-operating income | −1 | −2 | −3 | 0 |
| Income before tax | −6 | −22 | −27 | −24 |
| Net income from continuing operations | −6 | −22 | −27 | −24 |
| Net income | −6 | −22 | −27 | −24 |
| EPS, basic | −$0.03 | −$0.76 | −$0.80 | −$0.58 |
| EPS, diluted | −$0.03 | −$0.76 | −$0.80 | −$0.58 |
| Weighted average shares, basic | 201 | 37 | 37 | 40 |
| Weighted average shares, diluted | 201 | 37 | 37 | 40 |
| EBITDA | −5 | −21 | −27 | −30 |
| EBIT | −5 | −21 | −27 | −30 |